🟡 Medium ImpactPharma
Lupin gets U.S. FDA nod for new drug
Lupin gets U.S. FDA nod for new drug. The company has received approval for Glycerol Phenylbutyrate Oral Liquid, used in urea cycle disorder treatment. This expands Lupin’s presence in the U.S. specialty market. The drug had $28 million in U.S. sales over the past year.
📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDAApproval
#FDAApproval#Lupin#DrugLaunch
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →